Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Array BioPharma Inc Market Cap
Based on ratings from 13 stock analysts, the Array BioPharma Inc stock price is expected to increase by 70.24% in 12 months. This is calculated by using the average 12-month stock price forecast for Array BioPharma Inc. The lowest target is $15.00 and the highest is $35.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assignedARRY 6 buy ratings, 7 hold ratings, and 0 sell ratings. This means that analysts expect Array BioPharma Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARRY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| stephen byrd Morgan Stanley | Sell | $16.0 | maintained | Nov 2, 2022 |
Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.
When did it IPO
2020
Staff Count
1,058
Country
United States
Sector/Industry
Technology/Solar
CEO
Mr. Kevin G. Hostetler
Market Cap
$2.16B
In 2023, ARRY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARRY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
DNUT-USD
$13.32
ACVA-USD
$16.41
BLMN-USD
$26.6
$33.02
CORT-USD
$21.66
NMIH-USD
$29.05
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
